Insights › Market reaction

Why Syndax Pharmaceuticals (SNDX) Stock Fell 14.92% in 10 Minutes on Oct 12, 2026

190,166 shares changed hands in those 10 minutes.

Published in ET: Feed time in ET: Company news SNDX -14.92% in 10 min after the headline
  • SNDX fell 14.92% in the 10 minutes after the 16:01:00 ET headline, from $16.55 to $14.08.
  • The headline crossed in after-hours trading, 1 minute after the 4:00 ET close.
  • Next earnings report on the calendar: Monday, November 2, 2026.
SNDX Why Syndax Pharmaceuticals (SNDX) Stock Fell 14.92% in 10 Minutes on Oct 12, 2026
MoveSurge publish 16:01:00 ET
MoveSurge publish
16:01:00 ET
17.18 14.28 11.29 8.39 13.80 15:59 16:01 16:14
Real 1-minute OHLC candles around publish time. Chart times are New York ET; validated market data captured by MoveSurge.

Reaction by asset (real prices)

Asset2m beforeAt release+1m+10m+1m %+10m %
SNDX 16.55 16.55 10.00 14.08 -39.58% -14.92%

Syndax Pharmaceuticals (SNDX) shares fell 14.92% in the 10 minutes after this headline reached the MoveSurge news feed at 16:01:00 ET on Monday, October 12, 2026: “Syndax reports that the MAXPIRe Phase 2 trial of Axatilimab in Idiopathic Pulmonary Fibrosis did not achieve its primary endpoint.”

SNDX in the first 10 minutes

From a reference price of $16.55 just before the headline, the stock was down 39.58% after one minute and down 14.92%, at $14.08, after 10 minutes. Part of the first-minute move came back by the 10-minute mark. 190,166 shares changed hands in those 10 minutes. The headline crossed in after-hours trading, 1 minute after the 4:00 ET close.

Syndax Pharmaceuticals at a glance

SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
Market value$1.51 billion (as of Oct 11, 2026)
Next earnings report on the calendarMonday, November 2, 2026

Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.

What headline moved Syndax Pharmaceuticals stock on October 12, 2026?

At 16:01:00 ET, this headline crossed: “Syndax reports that the MAXPIRe Phase 2 trial of Axatilimab in Idiopathic Pulmonary Fibrosis did not achieve its primary endpoint.” The stock fell 14.92% in the next 10 minutes.

How far did SNDX move after the headline?

From $16.55 just before the headline to $14.08 10 minutes later, a -14.92% move.

When does Syndax Pharmaceuticals report earnings next?

The next report on the MoveSurge earnings calendar is Monday, November 2, 2026.

Sources

Never miss the next market-moving story

Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes recorded price reactions, search, watchlists, alerts and research tools.

Create free accountGo real time Watch live headlines -- free
See live news
The next market-moving story will not wait

See the important story while it still matters.

Seven market specialists bring experience dating back to 2006. MoveSurge adds the speed, coverage, and clear format built for today’s market.

Core market coverageEquities, macro, currencies and commodities Clear in secondsThe story, source, context, and measured move together Built on evidenceReal headlines, timestamps, prices, and trusted sources
Go real time View the live feed Subscription renews automatically. Cancel before renewal. Information only—no trade calls.